Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 4/20 | 0.44 |
| ▸ | F2R | P25116 | 2/20 | 0.42 |
| ▸ | IDH2 | P48735 | 1/20 | 0.42 |
| ▸ | POLQ | O75417 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24074165 | 0.89 | ALDH1A1 (0.48) | F2RPOLQ | |
| SCHEMBL30142800 | 0.89 | KDR (0.52) | F2RPOLQALOX15CNR1KDR | |
| SCHEMBL24074003 | 0.89 | KDR (0.52) | F2RPOLQALOX15CNR1KDR | |
| SCHEMBL30142663 | 0.89 | FBP1 (0.47) | F2RPOLQALOX15KDR | |
| SCHEMBL24074004 | 0.89 | FBP1 (0.47) | F2RPOLQALOX15KDR | |
| SCHEMBL24074006 | 0.88 | F2R (0.41) | F2RPOLQALOX15KDR | |
| SCHEMBL30142807 | 0.88 | F2R (0.41) | F2RPOLQALOX15KDR | |
| SCHEMBL24074000 | 0.87 | F2R (0.41) | F2RPOLQALOX15KDR | |
| SCHEMBL24074014 | 0.86 | F2R (0.40) | F2RPOLQALOX15KDR | |
| SCHEMBL30142767 | 0.86 | F2R (0.40) | F2RPOLQALOX15KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | PRSS12 1949/4885F2R 1930/4885IDH2 2254/4885 |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | PRSS12 1949/4885F2R 1930/4885IDH2 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.